BCIQ Profiles

Company Profile ReportTarget Profile Report

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma.

On the CAR T front, bluebird bio Inc. (NASDAQ:BLUE) reported data from seven evaluable patients in the Phase I CRB-402 trial to treat relapsed or refractory MM following at least three prior regimens

Read the full 656 word article

How to gain access

Continue reading with a
two-week free trial.